Your AFib patients deserve options
You know how much your patients with atrial fibrillation (AFib) worry about bleeding and the risk of stroke. You may also know that oral anticoagulants (OACs) aren’t a good fit for everyone. That’s why it’s so important to offer your patients an alternative to OACs with the WATCHMAN™ Implant.
One Time. For a Lifetime.
The WATCHMAN Implant is the one-time, minimally invasive procedure that protects your AFib patients for life – without the bleeding risk associated with OACs.
You can make a difference.
Determine which of your patients are eligible for WATCHMAN.
Proven1
- 500,000+ patients
- 10+ clinical trials
Safe2
- 99% implant success rate*
- 0.5% major adverse event rate**
Effective2
- 96.2% of patients discontinued OACs at 45 days
Meet Fred
85 years old
3 years with the WATCHMAN Implant
North Carolina
“It’s like having a big weight lifted off your shoulders.”
After a few trips to the ER for OAC-related bleeds, Fred knew he needed a different option to manage his AFib-related stroke risk. Fred received a WATCHMAN Implant and is now back to leading an active life without the fear of bleeding.
The WATCHMAN Implant is designed to treat a broad range of patient types.
Past bleed
A major or minor bleeding episode
Increased risk of future bleed
- Due to work or activities that increase risk of falling or bleeding
- Caused by other medications that increase bleeding risk
- Caused by side effects of OACs, such as bleeding risk based on HAS-BLED score or other factors
Increased risk of stroke
- Non-compliance
- Inability to maintain INR
![Medical professional in a blue shirt with quote: "I want to be proactive with [patient] care, not reactive."](/content/dam/watchman/en-us-hcp/landing-pages/physician-patient-conversation-video.jpg)
Which of your AFib patients may benefit from the WATCHMAN Implant?
The WATCHMAN Implant may be suitable for a broad range of non-valvular AFib (NVAF) patients and may be an appropriate option for your NVAF patients who meet these criteria. Eligible patients must:
- Have an increased risk of stroke and be recommended for OACs
- Be suitable for short-term OACs†
- Have an appropriate reason to seek a non-pharmacologic alternative to OACs
† Option for immediate DAPT-only post-implant drug regimen.
Resources for your patients
Watch a helpful video with your patients
This 3-minute video for patients includes information on AFib-related stroke risk and the WATCHMAN Implant procedure.
Connect your patients with a Patient Ambassador
Patient Ambassadors are people who have received the WATCHMAN Implant and have volunteered to share their personal experiences with potential patients.
Share the WATCHMAN patient site
Designed just for patients, this website explains how the WATCHMAN Implant works, offers a quick quiz about eligibility, explains cost information, and more.
* Procedure success defined as successful delivery and release of a WATCHMAN FLX device into the LAA
** Occurrence of one of the following events between the time of implant and within 7 days following the procedure or by hospital discharge, whichever is later: all-cause death, ischemic stroke, systemic embolism, or device or procedure related events requiring open cardiac surgery or major endovascular intervention.
References:
- Represents all WATCHMAN models.
- Kar S, Doshi SK, Sadhu A, et al. Primary outcome evaluation of a next-generation left atrial appendage closure device: Results from the PINNACLE FLX Trial. Circulation. 2021;143:1754–1762.